Article: No Shocker: VCs Remain Product-Focused Investors.

Washington Editor

JERSEY CITY, N.J. - It comes as no surprise to hear a panel of venture capitalists discuss their lack of interest in funding the earliest stages of biotech company development these days.

"Most venture funds aren't going to take that kind of risk," said Matt Rieke, a partner with Quaker Bioventures, during the third day of the Biotechnology Industry Organization's VentureForum East conference. Instead, VCs remain product-focused in an attempt to reap the quickest possible returns. Acknowledging that such an attitude produces a "missing link" for early stage companies and ideas, he urged entrepreneurs to look to alternate funding to ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!